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Autoantibodies to heat shock protein 90 (Hsp90) in breast cancer
patients have been reported to correlate with survival, the presence
of involved lymph nodes and metastatic occurrence (Jameel et al,
1993; Conroy et al, 1995; Conroy et al, 1998). Heat shock
proteins, which are highly conserved immunogenic proteins
performing intracellular chaperoning functions and preventing
cells from death, have been shown to be involved in tumour immu-
nity (Lindquist, 1986; Kaufmann, 1990; Suto et al, 1995). In
osteosarcoma cell lines, Hsp72 has been shown to be selectively
expressed on the cell surface and to be a target for natural killer
cells (Multhoff et al, 1997). It has been reported that Hsp27 is
overexpressed in human osteosarcomas (Uozaki et al, 1997) and
that Hsp72 is de novo expressed (Trieb et al, 1998). The Hsp72 de
novo expression correlates with a good response to neoadjuvant
chemotherapy and with Hsp60 expression. Additionally, T
lymphocytes specific for Hsps were isolated from human osteosar-
comas (Trieb et al, 1997). In osteosarcoma histological response to
chemotherapy is – in combination with initial tumour size – the
most important and generally accepted prognostic factor (Bentzen
et al, 1988; Davis et al, 1994; Bieling et al, 1996). But so far, diag-
nosis is limited to clinical symptoms, radiology and histology;
diagnostic laboratory tests are not available. Because anti-Hsp
antibodies have not been investigated in human osteosarcoma, it is
the aim of the study to determine anti-Hsp90 antibodies in sera
from osteosarcoma patients and correlate them with clinical
features.
MATERIALS AND METHODS
Patients
Sera from 20 patients (ten female, ten male, mean age: 18.6 years,
range 9–43) with high-grade osteosarcoma at the time of diagnosis
before biopsy and chemotherapy were analysed. The tumour was
located in the femur in 15 patients, in the tibia in four patients and
in the ilium in one patient. The mean duration of follow-up was 4.3
years (range 0.75–10 years). Informed consent was obtained from
the patients included in this study. Immediately following diag-
nosis, i.e. biopsy, all osteosarcoma patients then received full
neoadjuvant multiagent chemotherapy according to a protocol of
the German/Austrian/Swiss Cooperative Osteosarcoma Study trial
(Bieling et al, 1996). Surgical margins were defined histologically
according to the criteria of Enneking et al (1980) and were wide in
all cases except one marginal resection in a patient with lung
metastases.
Histologic analysis was done on the surgically resected tumours
with regard to tumour response to preoperative chemotherapy
according to the criteria of Salzer-Kuntschik (grade I–VI; Salzer-
Kuntschik et al, 1983). Response to preoperative chemotherapy
was considered as good when no or less than 10% viable tumour
cells (grade I–III) were found, whereas response was considered as
poor (grade IV–VI) when >10% viable tumour cells were found or
no effect of chemotherapy was seen.
Enzyme-linked immunosorbent assay
Antibody titres were tested by a solid-phase-bound antigen indi-
rect enzyme-linked immunosorbent assay (ELISA) as described
previously. Shortly, ELISA plates (Maxisorp, Nunc, Rosklide,
Denmark), precoated with 120 ml well–1 0.2% glutaraldehyde
(Sigma, Deisenhofen, Germany) were coated with 100 ml well–1
human Hsp90 (StressGen, Victoria, Canada, 5 mg ml–1) in
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Correspondence to: K Triebphosphate-buffered saline (PBS) (pH 7.2) and 0.1 M ethanolamine
in PBS 100 ml well–1 overnight at 4°C. Remaining solid phase
binding capacity was blocked (1 h at 37°C) by using 200 ml well–1
of 0.1 M ethanolamine in PBS (pH 7.2). After washing, serum
samples (100 ml well–1, diluted 1:100–500, 90 min, 37°C) were
tested for their antibody titres against Hsp90 by peroxidase-conju-
gated rabbit immunoglobulins to human immunoglobulins and
subsequently developed by ABTS. Extinction was read at
410 nm in an automatic ELISA reader (Dynatech, Santa Monica,
CA, USA), antibody titres were given as relative units ml–1 (U
ml–1) after subtraction of non-specific binding assessed with
ethanolamine. Specificity testing was performed in competitive
one-site indirect ELISAs. All densities were quantified without
knowledge of serum identity, i.e. blindly.
Statistical analysis
The association between anti-Hsp titres and clinical parameters
was estimated by the Mann–Whitney U-test. The significance
level was set at a value of P < 0.05. All values are given as
mean  ± S.D. and all tests were performed at least in duplicate.
RESULTS
Antibodies to Hsp90 could be detected in eight patients suffering
from osteosarcoma (8/20, 40%), the mean ± S.D. optical density
(OD) level was 0.06 ± 0.03 U ml–1 (range: 0.05–0.2). The presence
of anti-Hsp90 antibodies correlated with a good response to neoad-
juvant chemotherapy. Seventy-five per cent of the patients with a
positive anti-Hsp90 antibody titre had a good response to neoadju-
vant chemotherapy. In contrast, only 25% of the patients with anti-
Hsp90 negative sera had a good response (P < 0.05, Table 1).
Although only three patients exhibited metastases, a positive
correlation was found between the absence of anti-Hsp90 serum
antibodies and lung metastases at the time of diagnosis. All
patients with metastases were negative for anti-Hsp90 antibodies,
whereas no metastases were detected in patients with a positive
anti-Hsp90 titre (Table 1).
When anti-Hsp90 antibodies in osteosarcoma patients were
correlated with initial tumour size, duration of symptoms, alkaline
phosphatase serum levels, gender or age, no correlation was found
(data not shown).
DISCUSSION
The diagnosis of osteosarcoma, the most frequent malignant bone
tumour, is still limited to clinic symptoms, radiology and
histology, but so far, an undisputed serological marker is not avail-
able for the prognosis of osteosarcoma, although a variety of
markers has been investigated. For instance the prognostic value
of alkaline phosphatase (AP) and lactate dehydrogenase (LDH)
serum levels are controversial. Some groups reported a correlation
of pretreatment levels within the normal range of the two enzymes
with a better outcome (Bacci et al, 1996), whereas others could
only find a correlation for LDH, but not for AP (Pochanugool et al,
1997). A correlation only in patients without metastases, but not in
such with metastases has been reported (Meyers et al, 1993). Other
serum factors like erythrocyte sedimentation rate were found to be
not of prognostic value. Tumour size and histologic response to
preoperative chemotherapy have been shown to be the most
important prognostic factors, whereas age, gender or localization
are of minor prognostic value (Bentzen et al, 1988; Bieling et al,
1996; Pochanugool et al, 1997; Saeteret al, 1997).
In contrast to serum, in tumour tissue several prognostic
markers have been identified, for instance P-glycoprotein, ErbB-2,
genetic aberrations or Hsp72 (Baldini et al, 1995; Onda et al,
1995; Trieb et al, 1998; Tarkkanen et al, 1999). In breast cancer it
has been shown that the overexpression of Hsps in the tumour
must not correlate with serum antibody levels (Conroy et al,
1995). The immune response against Hsps must not necessarily a
general, uniform cellular and humeral response. Autoantibodies
against Hsp90 in breast cancer patients have been reported to
correlate with survival, the presence of involved lymph nodes and
metastatic occurrence (Jameel et al, 1993; Conroy et al, 1995,
1996, 1998). It was, therefore, an aim of this study to investigate
whether anti-Hsp antibodies could serve as a predictive marker at
the time of diagnosis, because non-response to chemotherapy is
one of the main problems in the treatment of osteosarcoma. Our
results suggest that the humoural immune response to Hsp90
might be of predictive value, because the presence of anti-Hsp90
antibodies correlates with a good response to neoadjuvant
chemotherapy and the absence of anti-Hsp90 antibodies correlates
with occurrence of metastases.
The mechanism of the protective effect of Hsp90 is not yet
clarified, it might be accompanied by an immune response to the
associated Hsp or by a direct protective effect of anti-Hsp90 anti-
bodies. Transfection of tumours with Hsps in vivo resulted in the
rejection of the tumour by development of an immune response
and tumour cells transfected with Hsps in vitro lost tumorigenicity
as compared to untransfected cells (Lukacs at al, 1997).
These observations should stimulate evaluation of the role of
Hsp90 in drug resistance in osteosarcoma. After testing a represen-
tative sample of sera from patients suffering from osteosarcoma,
an entity with a low incidence, we found that anti-Hsp90 anti-
bodies could, among others, act as new predictive markers in
osteosarcoma. To further confirm our findings, a larger number of
patients needs to be studied.
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Table 1 Anti-hsp90 antibodies in sera of osteosarcoma patients (n = 20) in
correlation with response to neoadjuvant chemotherapy and appearance of
metastases
Osteosarcoma patients
Hsp90-positive Hsp90-negative P-valuea
(n=8) (n=12)
Response < 0.05
Poor 2 (25%) 9 (75%)
Good 6 (75%) 3 (25%)
Metastases
Yes 0 (0%) 3 (25%)
No 8 (100%) 9 (75%)
a Sera for Hsp90 antibodies positive vs. negative (Mann–Whitney U-test).REFERENCES
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